ATE251636T1 - O-glycaninhibitoren von selectinvermittelten entzüngen - Google Patents
O-glycaninhibitoren von selectinvermittelten entzüngenInfo
- Publication number
- ATE251636T1 ATE251636T1 AT96928073T AT96928073T ATE251636T1 AT E251636 T1 ATE251636 T1 AT E251636T1 AT 96928073 T AT96928073 T AT 96928073T AT 96928073 T AT96928073 T AT 96928073T AT E251636 T1 ATE251636 T1 AT E251636T1
- Authority
- AT
- Austria
- Prior art keywords
- glycans
- selectin
- glycan
- beta
- disialylated
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 abstract 2
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 abstract 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 abstract 1
- 102000008212 P-Selectin Human genes 0.000 abstract 1
- 108010035766 P-Selectin Proteins 0.000 abstract 1
- NIGUVXFURDGQKZ-KRAHZTDDSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-KRAHZTDDSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 150000004044 tetrasaccharides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51092095A | 1995-08-03 | 1995-08-03 | |
| US1779496P | 1996-05-15 | 1996-05-15 | |
| US64980296A | 1996-05-17 | 1996-05-17 | |
| PCT/US1996/012820 WO1997006176A2 (en) | 1995-08-03 | 1996-08-02 | Peptide and o-glycan inhibitors of selectin mediated inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE251636T1 true ATE251636T1 (de) | 2003-10-15 |
Family
ID=27360885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96928073T ATE251636T1 (de) | 1995-08-03 | 1996-08-02 | O-glycaninhibitoren von selectinvermittelten entzüngen |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0850243B1 (enExample) |
| JP (1) | JPH11510543A (enExample) |
| KR (1) | KR100523506B1 (enExample) |
| AT (1) | ATE251636T1 (enExample) |
| AU (1) | AU723262B2 (enExample) |
| CA (1) | CA2228512A1 (enExample) |
| DE (1) | DE69630307T2 (enExample) |
| DK (1) | DK0850243T3 (enExample) |
| ES (1) | ES2208759T3 (enExample) |
| MX (1) | MXPA98000968A (enExample) |
| WO (1) | WO1997006176A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| US20030143662A1 (en) | 1998-06-16 | 2003-07-31 | Cummings Richard D. | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof |
| AU773542B2 (en) | 1998-06-16 | 2004-05-27 | Board Of Regents Of The University Of Oklahoma, The | Glycosulfopeptides and methods of synthesis and use thereof |
| US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
| EP1131084A4 (en) * | 1998-10-30 | 2001-12-19 | Genetics Inst | INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL) |
| CA2347940A1 (en) * | 1998-11-21 | 2000-06-02 | The Regents Of The University Of California | Use of core 2 glcnac transferase inhibitors in treating inflammation |
| US6492152B1 (en) | 1999-06-15 | 2002-12-10 | The Board Of Regents Of The University Of Oklahoma | Core 1 β3-galactosyl transferases and methods of use thereof |
| US7256171B1 (en) | 1999-11-20 | 2007-08-14 | The Regents Of The University Of California | Use of core 2 G1cNAc transferase inhibitors in treating inflammation |
| EP1325123A4 (en) * | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS |
| EP1406930A4 (en) * | 2000-12-29 | 2007-01-10 | Savient Pharmaceuticals Inc | "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF" |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| AU2003255337A1 (en) * | 2002-07-31 | 2004-02-23 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
| JP4599027B2 (ja) * | 2002-10-30 | 2010-12-15 | 東洋水産株式会社 | Ｌ−セレクチン結合阻害剤 |
| FI20021989A0 (fi) * | 2002-11-06 | 2002-11-06 | Halina Miller-Podraza | Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö |
| GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
| GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
| US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| MXPA06012987A (es) | 2004-05-11 | 2007-06-12 | Abgenomics Corp | Epitopos inductores de muerte de celulas t. |
| GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
| GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
| US20070298034A9 (en) * | 2005-12-09 | 2007-12-27 | Angela Widom | Sulfotyrosine specific antibodies and uses therefor |
| JP5331293B2 (ja) * | 2006-04-28 | 2013-10-30 | 公益財団法人野口研究所 | 多様性を表現するオリゴ糖またはその誘導体 |
| PT2321235T (pt) * | 2008-09-02 | 2019-06-25 | Construction Research & Technology Gmbh | Utilização de uma composição aceleradora de endurecimento que contém plastificante |
| BR112012009500A2 (pt) * | 2009-10-21 | 2016-11-29 | Eth Zuerich | utilidade médica de proteínas de ligação de glicano e glicanos |
| US20130209449A9 (en) | 2011-06-13 | 2013-08-15 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
| KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| EP3595720A4 (en) | 2017-03-14 | 2021-05-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU681369B2 (en) * | 1992-11-16 | 1997-08-28 | Board Of Regents Of The University Of Oklahoma, The | Glycoprotein ligand for P-selectin and methods of use thereof |
| WO1995030001A2 (en) * | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
-
1996
- 1996-08-02 KR KR10-2004-7004565A patent/KR100523506B1/ko not_active Expired - Fee Related
- 1996-08-02 MX MXPA98000968A patent/MXPA98000968A/es not_active IP Right Cessation
- 1996-08-02 CA CA002228512A patent/CA2228512A1/en not_active Abandoned
- 1996-08-02 EP EP96928073A patent/EP0850243B1/en not_active Expired - Lifetime
- 1996-08-02 DK DK96928073T patent/DK0850243T3/da active
- 1996-08-02 WO PCT/US1996/012820 patent/WO1997006176A2/en not_active Ceased
- 1996-08-02 JP JP9508625A patent/JPH11510543A/ja active Pending
- 1996-08-02 ES ES96928073T patent/ES2208759T3/es not_active Expired - Lifetime
- 1996-08-02 AU AU67669/96A patent/AU723262B2/en not_active Ceased
- 1996-08-02 DE DE69630307T patent/DE69630307T2/de not_active Expired - Fee Related
- 1996-08-02 AT AT96928073T patent/ATE251636T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997006176A2 (en) | 1997-02-20 |
| KR100523506B1 (en) | 2005-10-24 |
| KR20040039440A (ko) | 2004-05-10 |
| CA2228512A1 (en) | 1997-02-20 |
| DE69630307D1 (de) | 2003-11-13 |
| DE69630307T2 (de) | 2004-07-15 |
| JPH11510543A (ja) | 1999-09-14 |
| EP0850243B1 (en) | 2003-10-08 |
| MXPA98000968A (es) | 2002-07-15 |
| DK0850243T3 (da) | 2004-02-02 |
| EP0850243A2 (en) | 1998-07-01 |
| WO1997006176A3 (en) | 1997-07-24 |
| AU6766996A (en) | 1997-03-05 |
| ES2208759T3 (es) | 2004-06-16 |
| AU723262B2 (en) | 2000-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0850243T3 (da) | O-Glycaninhibitorer af selectinmedieret inflammation | |
| Krusius et al. | Structural features of tissue glycoproteins: fractionation and methylation analysis of glycopeptides derived from rat brain, kidney and liver | |
| ATE246455T1 (de) | Kohlenhydratmischung | |
| Lamblin et al. | Primary structure determination of five sialylated oligosaccharides derived from bronchial mucus glycoproteins of patients suffering from cystic fibrosis. The occurrence of the NeuAc alpha (2----3) Gal beta (1----4)[Fuc alpha (1----3)] GlcNAc beta (1----.) structural element revealed by 500-MHz 1H NMR spectroscopy. | |
| CA2261597A1 (fr) | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| Serafini-Cessi et al. | Guinea-pig kidney β-N-acetylgalactosaminyltransferase towards Tamm-Horsfall glycoprotein. Requirement of sialic acid in the acceptor for transferase activity | |
| CA2110386A1 (en) | Method for the Enzymatic Synthesis of Alpha-Sialylated Oligosaccharide Glycosides | |
| DK1105002T3 (da) | Kulhydratblandinger | |
| IL86881A0 (en) | Polysaccharides extractred from plants,their preparation and pharmaceutical compositions containing them | |
| Kobata et al. | Oligosaccharides of Human Milk: II. ISOLATION AND CHARACTERIZATION OF A NEW PENTASACCHARIDE, LACTO-N-FUCOPENTAOSE III | |
| ES2055270T3 (es) | Uso de l-azucares para la fabricacion de composiciones laxantes. | |
| Wieruszeski et al. | Structure of two new oligosaccharides isolated from human milk: sialylated lacto-N-fucopentaoses I and II | |
| Warren et al. | The membrane glycoproteins of the malignant cell | |
| CA2071265A1 (en) | Gel | |
| ATE41785T1 (de) | Membranoese polysaccharide, verwendbar insbesondere als arzneimittel und verfahren zu ihrer herstellung. | |
| Nergard et al. | Structure-immunomodulating activity relationships of a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp. | |
| da Silva et al. | Carbohydrate, glycopeptide and protein components of the lichen Sticta sp. and effect of storage | |
| ATE239042T1 (de) | Wasserlösliches arabinogalactan, das mit lipophilen gruppen derivatisiert ist | |
| Ng et al. | Relationship of structure to function in bacterial endotoxins. IX. Differences in the lipid moiety of endotoxic glycolipids | |
| Lloyd et al. | Immunochemical studies on blood groups. XXXVII. The structures of difucosyl and other oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Optical rotatory dispersion and circular dichroism spectra of these oligosaccharides | |
| Kitajima et al. | Analytical methods for identifying and quantitating deamidated sialic acid (2-keto-3-deoxy-d-glycero-d-galactonononic acid) and α2→ 8-linked poly (oligo) nonulosonate residues in glycoconjugates | |
| WO1997021416A3 (es) | Glicoconjugados de substancias opiaceas | |
| Savage et al. | Structural characterization of sialylated tetrasaccharides and pentasaccharides with blood group H and Lex activity isolated from bovine submaxillary mucin | |
| Ansari et al. | Structural studies of the O-antigen from Vibrio cholerae O: 21 | |
| Hellerqvist et al. | Structural studies of the O-specific side-chains of the cell-wall lipopolysaccharide from Salmonella senftenberg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0850243 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |